MS spasticity

Results from a Phase 2 proof-of-concept study of ADS-5102 (amantadine HCl), showing that multiple sclerosis patients given the extended-release oral treatment improved their walking speed, will be presented at ACTRIMS 2017 this week. Findings in the poster, “A Phase 2 Study of ADS-5102 (amantadine hydrochloride) Extended Release Capsules in Multiple Sclerosis Patients with Walking Impairment,”…

The French economic promotion agency Bpifrance has awarded Boston-based PathMaker Neurosystems a grant to finance the development of its MyoRegulator, a noninvasive neurotherapy technology to treat conditions linked to neural pathway disruption, including neuromotor spasticity in patients with multiple sclerosis (MS). Through the Programme d’Investissements d’Avenir (PIA-1), an investment program offered by Bpifrance, the  grant — whose…

The U.S. Food and Drug Administration (FDA) has authorized the use of Bioness’ L300 Go System electrical-stimulation rehabilitation device for multiple sclerosis (MS) patients and others with walking impairment. It is the first electrical stimulation device to offer 3D motion detection of gait and muscle activation, the company says. The L300…

Want to know what living with MS feels like? Take a ride on this bike. Those of us who have MS know that our disease has lots of symptoms. There are the legs that feel like they have 20-pound weights on them … balance that can have you…

A new clinical trial evaluating the effectiveness of extended-release baclofen capsules in relieving spasticity related to multiple sclerosis (MS) is calling for 135 people with any form of the disease. The study, taking place in six U.S. states, is sponsored by Sun Pharma, the drug’s developer. Baclofen, an approved MS…

After my recent insurance experience, which I share here, I never again will wonder why some people give up on claiming their medical benefits. I have received Botox treatment for spasticity of my quad and hamstring muscles. This is an FDA-approved use, but to get this treatment there has…

Certain cannabinoids reduce spasticity symptoms in multiple sclerosis (MS) patients, according to a report  from the National Academies of Sciences, Engineering, and Medicine that scrutinized published research about the benefits and hazards of cannabis and cannabinoid use. Cannabinoids also show proven effect in other areas that may be important to MS patients, but they are linked…

This video from Dulci Hill addresses the topic of walking aids. Many multiple sclerosis patients may feel unstable or fatigued when walking and using a cane, wheeled walker or mobility scooter may help to provide stability, aid balance and help you to get around and keep your independence.

Multiple sclerosis is so weird. Sometimes I just put up with a strange sensation or painful problem because I do not know how to describe it to the doctor without sounding crazy. I hope the problems will just go away, and sometimes they do. Maybe I am a little…

Voters in four U.S. states on Nov. 8 chose to legalize the recreational use of marijuana, and those in three other states approved the medicinal use of cannabis — all gains for pharmaceutical and other companies designing cannabis-based therapies for people with long-term chronic ills whose symptoms might be helped with these…

Medical Marijuana announced that Axim Biotechnologies, a cannabinoid-based product developer in which it owns a strategic interest, has released a product pipeline chart highlighting development timelines for its cannabinoid-based therapeutics, including those for  multiple sclerosis (MS) patients. The  chart illustrates the stage each drug is in, from preclinical testing to, eventually, applications for regulatory…

AXIM Biotech has closed on a private funding round that will enable it to continue clinical trials for a variety of conditions, including its pharmaceutical candidate MedChew Rx, a patented cannabinoid release chewing gum for treating pain and spasticity in multiple sclerosis (MS). According to a press release from SECFilings.com,…

AXIM Biotechnologies  announced it has secured financing from private sources to continue its testing of medical cannabinoid products as potential treatments for multiple indications, including pain and spasticity in people with multiple sclerosis (MS). Specifically, AXIM  is testing pharmaceutical delivery systems and active ingredients for its medical marijuana line. “This financing provides us with…

PathMaker Neurosystems is the winner of the Universal Biotech Innovation Prize 2016 for its innovative, non-invasive neurotherapy technologies to treat conditions linked to neural pathway disruption, including multiple sclerosis (MS). The selection was announced at Innovation Days, an international event honoring the best in the life sciences and held in Paris on Oct. 3–4. Launched in 2009 by a…

A new study shows that an enzyme called hyaluronidase may be effective in reducing muscle spasticity resulting from neurological disorders such as multiple sclerosis. The results were published in a study titled “Human Recombinant Hyaluronidase Injections For Upper Limb Muscle Stiffness in Individuals With Cerebral Injury: A Case Series,”…

When I first heard about MS “foot drop,” I assumed that the manifestation of this symptom would be a sudden and obvious inability to walk properly.  I knew many people with MS who used canes and walked with significant stiffness or a “dragging” limb. I filed “foot drop” away…

The other day I received a very troubling direct message from someone on another Multiple Sclerosis website: “I was diagnosed with MS in 2004 but, foolishly, dismissed it. Other than bad spacisity [spasticity] and a few little episodes, I was relatively symptom free. That is until…

Don’t you just love the walking test when you see your neurologist for your annual exam? “Let’s see how fast you can walk to me,” she says. The test is called the T25-FW, and it measures how long it takes you to walk 25 feet. But, what about how…

Transcutaneous electrical nerve stimulation (TENS) might be an option to treat spasticity, one of the more common symptoms of multiple sclerosis (MS), according to a literature review conducted by researchers from Universidad de Castilla la Mancha, Toledo and Hospital Nacional de Parapléjicos de Toledo, in Spain.

Flex Pharma, Inc., announced the start of a Phase 2 clinical trial assessing the safety and efficacy of FLX-787 in multiple sclerosis (MS) patients who suffer from cramps, spasms, and/or spasticity as a result of the disease. The trial is being run in conjunction with Neuroscience Trials Australia. Flex Pharma’s FLX-787 is a single molecule,…

Adamas Pharmaceuticals recently reported positive results from its Phase 2 proof-of-concept clinical trial evaluating ADS-5102 (amantadine HCl), an extended-release version of amantadine, in multiple sclerosis (MS) patients with difficulties in walking. The trial (NCT02471222), a double-blind, placebo-controlled and two-arm parallel group study, evaluated ADS-5102 given once daily at 340 mg, at bedtime, for four…

Researchers from Mount Sinai Rehabilitation Hospital found that patients with multiple sclerosis (MS) who complain of speech limitations or difficulty in swallowing cannot produce specific phonemes, which may be a helpful way of objectively quantifying these symptoms in MS patients. The findings were recently reported in an oral presentation titled “Rate of…

PathMaker Neurosystems, Inc., recently announced the launch of an Institutional Review Board (IRB)-approved clinical trial, in partnership with Northwell Health (formerly North Shore-LIJ Health System) and The Feinstein Institute for Medical Research, to evaluate the safety and efficacy of MyoRegulator for the treatment of spasticity, one of the most common symptoms in multiple sclerosis…

MedChew Rx, by AXIM Biotechnology, the world’s first patented cannabinoid release chewing gum for pain and spasticity in multiple sclerosis (MS), is moving into clinical testing. If all goes well, the company plans for a global release date of 2017. Medical cannabis is believed to have considerable promise as a therapy for…

In a new study, researchers evaluated the effect of dalfampridine treatment in people with multiple sclerosis (MS) and observed significant improvements in not only walking speed and distance, but also in gait and balance. The paper, titled “Dalfampridine Effects Beyond Walking Speed in Multiple Sclerosis,” was published in the…

PathMaker Neurosystems Inc., a clinical-stage neuromodulation company focused on non-invasive therapies for neuromotor disorders, recently announced that the U.S. Food and Drug Administration (FDA) has granted the company’s MyoRegulator™ PM-2200 system the Expedited Access Pathway (EAP) designation and priority processing status. The MyoRegulator is the first product of PathMaker…

Barcelona, Spain-based, global pharma firm Almirall presented new clinical evidence at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) — held in Barcelona October 7–10, 2015 — supporting the efficacy of its Sativex product, currently the only pharmaceutical medicine derived from cannabinoids…

Osmotica Pharmaceutical Corp. recently announced that the FDA accepted its New Drug Application (NDA) for OntinuaTM ER.

AXIM Biotechnologies, Inc. (AXIM)’s clinical trials testing a new pharmaceutical-grade cannabis chewing gum treatment option for Multiple Sclerosis (MS) pain and spasticity are drawing lots of popular and specialty media attention, with reports in Multiple Sclerosis News Today, Marketwatch, Yahoo! Finance, Wall Street Journal, CNN Money,…

AXIM Biotechnologies, Inc., a biotechnology company focused on global research, development and production of pharmaceutical, nutraceutical, food and cosmetic products derived from industrial hemp, has announced commencement of clinical development of its leading patented pharmaceutical chewing gum, MedChew RX, for registration as a drug for relieving pain and/or spasticity…